Interesting look to me. Looking for move above $17.02 for possible failed breakdown. Earnings on 11/6. Past earnings moves have caused stock to move 10% +/- .
I really thought it'd hold the line but it didn't. However, I'm still holding stocks and few options. Many other medical stocks have shown more than enough ER beat. Will probably hold tis through ER.
Hi guys,
Invitae is a leader in advanced medical genetics.
UnitedHealthcare created a "Preferred Laboratory Network (PLN)".Invitae has been selected as one of the seven lab companies.
Long:
LMT 1- 18.9$ (25 % of the planned investment amount)
LMT 2- 17.34$ (55 % of the planned investment amount)
LMT 3- 14.79$ (20 % of the planned investment...
Looks like NVTA is continuing its uptrend. Currently looks like the possibility for a slight pull back at resistance accompanied by divergence in MACD and pricing. Once pullback is complete, opportunity for completing 5 waves is still there.
He may not be to the liking of all, but when Andrew left makes a trade public it moves the stock, that is exactly what happened to NYSE:NVTA in today's trading.
"I am long a lot," Left told TheStreet, adding that he thinks NVTA could hit $100 a share two years from now. He also said it's very possible that the company will be acquired before reaching that level....
NVTA gave opportunity today (3/25/19) to lighten up at $25.5 (retest of resistance). Looking for 21 EMA retest and add on point. Overall still bullish but needs time to digest gains.
Price above the cloud ( bullish )
Above 200MA ( bullish )
Buy $19.22
Take Profit: 24.00 R=2
Stop Loss: $16.83
Not Financial Advice
Thank You
All comments are welcome
The market God's have spoken in my eyes nvta is destined to break out to the $16-20 range. Fundamentals support this plan along with general beta weight. Technicals giving a potential green light possibly next week?
If your not in yet then you should get in. Wait for the panic and accumulate as much as possible. It is the next Kondratieff cycle of innovation leading the world forward.
en.wikipedia.org Rest in peace my friend.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
NVTA
